XJPX
4094
Market cap268mUSD
Oct 09, Last price
2,170.00JPY
1D
-0.46%
1Q
4.28%
Jan 2017
140.31%
Name
Nihon Kagaku Sangyo Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nihon Kagaku Sangyo Co., Ltd., a company founded in Tokyo, Japan, in 1924, specializes in the production and global distribution of a broad spectrum of industrial chemicals and construction supplies. Its chemical offerings include an extensive range of inorganic metal compounds, such as those derived from copper, tin, nickel, cobalt, bismuth, chromium, manganese, antimony, zinc, iron, and lithium. The company also manufactures organic metal compounds like metal acetylacetonate complexes, metallic soaps, PUCAT, and PA series products. Furthermore, it provides various surface treatment agents, covering anodized aluminum treatments, electroplating solutions, brighteners, additives, electroless plating agents, etchants, and rust prevention formulations. These chemicals are vital components in diverse industries, from plastics, textiles, paints, and inks to electronics, and advanced fields such as optical communications and modern battery technologies, including secondary and fuel cells. In addition to its chemical division, Nihon Kagaku Sangyo develops and supplies building materials, including fire-resistant, waterproof, and ventilation products. Its portfolio also features Cool Fin heat exchangers, stainless-steel architectural elements like handrails and mailboxes, custom-fabricated metal components for industrial applications, and specialized materials for roof eaves.
Key people
Eiji Yanagisawa
Chairman of the Board · since 2024
Hiroki Kadoya
President, Representative Director · since 2025
Takeyuki Ohta
Senior Managing Executive Officer, Chief Director of Administration, Director of General Affairs, Director · since 2025
Osamu Matsuo
Managing Executive Officer, Chief Senior Director of Pharmaceutical Business · since 2025
Isao Onomura
Managing Executive Officer · since 2024
Osamu Yamada
Managing Executive Officer, Chief Director of Pharmaceutical Sales in Main Pharmaceutical Business Supervision Unit, Director of Marketing · since 2023
Koji Sato
Executive Officer, Chief Director of Building Materials, Director of Building Materials Sales, Manager of Housing Materials Group · since 2025
Ichiro Takasaki
Executive Officer, Chief Director of Pharmaceutical Production in Main Pharmaceutical Business Supervision Unit, Manager of Production Management Office, Manager of Quality Assurance Office · since 2025
Juntaka Watanabe
Executive Officer, Manager of R&D Center in Main Pharmaceutical Business Supervision Unit, Director of Research · since 2024
Yutaka Yoshida
Executive Officer, Director of Business Planning Office · since 2025
Akira Yamamoto
Managing Executive Officer, Director · since 2024
Takeshi Hachimura
Independent Director · since 2018
Independent Director · since 2023
Junko Taki
Independent Director · since 2022
IPO date
Oct 02, 1961
Employees
442
Domiciled in
JP
Incorporated in
JP
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||